EDGEWISE THERAPEUTICS

edgewise-therapeutics-logo

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewiseโ€™s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

#SimilarOrganizations #People #Financial #Website #More

EDGEWISE THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Health Care

Founded:
2017-01-01

Address:
Boulder, Colorado, United States

Country:
United States

Website Url:
http://www.edgewisetx.com

Total Employee:
11+

Status:
Active

Contact:
720.262.7002

Email Addresses:
[email protected]

Total Funding:
160.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome


Similar Organizations

arcutis-biotherapeutics-logo

Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.

roivant-sciences-logo

Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.

wren-therapeutics-logo

Wren Therapeutics

Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.


Current Advisors List

peter-thompson_image

Peter Thompson Board Member @ Edgewise Therapeutics
Board_member

Current Employees Featured

kevin-koch_image

Kevin Koch
Kevin Koch CEO @ Edgewise Therapeutics
CEO

alan-russell_image

Alan Russell
Alan Russell Co-Founder & Chief Scientific Officer @ Edgewise Therapeutics
Co-Founder & Chief Scientific Officer
2017-07-01

joanne-m-donovan_image

Joanne M. Donovan
Joanne M. Donovan Chief Medical Officer @ Edgewise Therapeutics
Chief Medical Officer

rmichael-carruthers_image

R.Michael Carruthers
R.Michael Carruthers Chief Financial Officer @ Edgewise Therapeutics
Chief Financial Officer
2020-09-01

badreddin-edris_image

Badreddin Edris
Badreddin Edris Co-Founder @ Edgewise Therapeutics
Co-Founder
2018-03-01

Founder


alan-russell_image

Alan Russell

badreddin-edris_image

Badreddin Edris

peter-thompson_image

Peter Thompson

Stock Details


Company's stock symbol is NASDAQ:EWTX

Investors List

new-leaf-ventures_image

New Leaf Ventures

New Leaf Ventures investment in Series C - Edgewise Therapeutics

viking-global-investors_image

Viking Global Investors

Viking Global Investors investment in Series C - Edgewise Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - Edgewise Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Edgewise Therapeutics

us-venture-partners_image

U.S. Venture Partners

U.S. Venture Partners investment in Series C - Edgewise Therapeutics

surveyor-capital_image

Surveyor Capital

Surveyor Capital investment in Series C - Edgewise Therapeutics

cureduchenne-ventures_image

CureDuchenne Ventures

CureDuchenne Ventures investment in Series C - Edgewise Therapeutics

deerfield_image

Deerfield

Deerfield investment in Series C - Edgewise Therapeutics

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series C - Edgewise Therapeutics

citadel_image

Citadel

Citadel investment in Series C - Edgewise Therapeutics

Official Site Inspections

http://www.edgewisetx.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.64 K

  • Host name: a9a78e7bfea26d463.awsglobalaccelerator.com
  • IP address: 13.248.152.34
  • Location: Seattle United States
  • Latitude: 47.6348
  • Longitude: -122.3451
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98109

Loading ...

More informations about "Edgewise Therapeutics" on Search Engine

Edgewise Therapeutics - Crunchbase Company Profile & Funding

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization. Boulder, Colorado, United States. 51 โ€ฆSee details»

Pipeline | Edgewise

Our Pipeline. Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a โ€ฆSee details»

Company | Edgewise

Our Vision. Our vision is to improve the lives of patients and families suffering from rare muscle disorders by building the worldโ€™s leading muscle-focused, precision medicine company. Key components of our strategy to achieve this vision include:See details»

Edgewise Therapeutics, Inc. - Investor Relations

Corporate Profile. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments โ€ฆSee details»

Edgewise Receives U.S. FDA Fast Track Designation for EDG โ€ฆ

BOULDER, Colo., February 13, 2024 -- ( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โ€ฆSee details»

Clinical Trials | Edgewise

Edgewise is committed to developing new therapies for people living with severe, genetic neuromuscular or cardiac disorders. Novel therapies require years of laboratory โ€ฆSee details»

A Novel Approach to Tackling Rare Progressive Muscle Disorders

Edgewise Therapeutics is a Clinical-Stage Company Focused on Advancing Innovative Treatments for Severe, Rare Muscle Disorders . 3. Plan to enhance portfolio from โ€ฆSee details»

Edgewise Therapeutics Begins Dosing First-in-Human

Sep 14, 2023 Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac โ€ฆSee details»

Areas of Focus | Edgewise

With our novel drug discovery platform, and our combined expertise in muscle physiology and small molecule drug design, Edgewise Therapeutics is working to change the future. Edgewise is currently โ€ฆSee details»

Edgewise Therapeutics Announces Positive Two-Year Topline

Apr 15, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the โ€ฆSee details»

Edgewise Therapeutics - Funding, Financials, Valuation & Investors

Edgewise Therapeutics is registered under the ticker NASDAQ:EWTX . Their stock opened with $16.00 in its Mar 26, 2021 IPO. Edgewise Therapeutics is funded by 15 โ€ฆSee details»

Edgewise Therapeutics Reports Fourth Quarter and Full Year โ€ฆ

Feb 22, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and โ€ฆSee details»

Edgewise Therapeutics Announces Positive Two-Year Topline โ€ฆ

BOULDER, Colo., April 15, 2024 -- ( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โ€ฆSee details»

2024-04-23 | NDAQ:EWTX | Press Release | Edgewise โ€ฆ

4 days ago About Edgewise Therapeutics. Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular โ€ฆSee details»

Edgewise Therapeutics Announces Initiation of GRAND โ€ฆ

Sep 26, 2023 BOULDER, Colo.โ€“ (BUSINESS WIRE)โ€“ Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โ€ฆSee details»

Edgewise Therapeutics - Contacts, Employees, Board Members, โ€ฆ

Organization. Edgewise Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 8. โ€ฆSee details»

Edgewise Therapeutics to Present on EDG-5506 for the โ€ฆ

BOULDER, Colo., February 28, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the โ€ฆSee details»

EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TWO โ€ฆ

Apr 16, 2024 Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker โ€ฆSee details»

Edgewise Therapeutics, Inc. - Governance - Board of Directors

Edgewise Therapeutics, Inc. - Governance - Board of Directors. Board of Directors. Peter Thompson, M.D. Chairman and Co-Founder. Peter Thompson, M.D., serves as a โ€ฆSee details»

Series C - Edgewise Therapeutics - 2020-12-08 - Crunchbase

Dec 8, 2020 Overview. Organization Name. Edgewise Therapeutics. Announced Date Dec 8, 2020. Funding Type Series C. Funding Stage Late Stage Venture. Money Raised. $95M. Pre-Money Valuation $200M. Lead Investors.See details»